Two new clinical reports address screening and management of autism spectrum disorders by pediatricians; they replace the American Academy of Pediatrics 2001 policy statement and technical report. Medscape Medical News
A recent Phase II study has demonstrated that oral FTY720 is effective in reducing disease activity in relapsing multiple sclerosis with a favorable adverse-effect profile. These results are awaiting confirmation in the three ongoing Phase III clinical trials Expert Review of Neurotherapeutics
